It has demonstrated interesting results in the BROCADE3 trial as a maintenance monotherapy following chemotherapy of veliparib in combination with carboplatin/paclitaxel for HER2− advanced germline gBRCAm BC [238,239]. The gene discussed is ERBB2; the disease is breast cancer.